Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Chuca Marsh who wrote (7705)	2/13/2000 12:04:00 PM
From: Chuca Marsh	Read Replies (2) \| Respond to of 8116

!! AxCell !! IS- What happened with the Library, both TRAILS LED to DuPont Merck, so what happened??? Chucka informagen.com 1. Genelabs Technologies Inc of Redwood, California is a global biopharmaceutical and diagnostics company focused on gene-regulating drug discovery; infectious diseases including hepatitis; and immunological disorders including lupus. The company's lead pharmaceutical compound GL701, is in Phase III clinical trials as a new therapy for systemic lupus erythematosus. The lead research program is based on its proprietary enabling technology, MERLIN for creating gene-specific, small organic, DNA-binding molecules. Additional research efforts are underway in the area of genomics for the identification of novel immunomodulatory genes. Genelabs is located in Redwood City, California, with operations in Geneva, Taiwan and Singapore. (97/NR) 2. Genelabs Technologies, Inc. is a human health care company that is discovering, developing and commercializing products to diagnose, prevent and treat viral diseases and cancer. Si and informagen.com (--/--) joint venture between Dupont and Merck. subsidiary: DuPont Radiopharmaceuticals - worldwide leader in radiopharmaceuticals - Billerica MA 1-800-635-2683 (94/--) stopped selling Teflon & materials to device manufacturers because of potential for legal liabilities. (R) (96/12) $20 million research, development and licensing collaboration with DuPont Merck applying Genelabs Merlin assay re: drug discovery. (FW) (95/12) $55 million research and development collaboration between Mitotix and DuPont Merck Pharmaceutical re: cyclin-dependent kinases & gene p16 - anti-cancer. (FW) (95/05) technology I found it, AxCell...it has been a while, folks: cytogen.com "This partnership demonstrates Compaq's commitment to our continued efforts to provide solutions for the pharmaceutical industry," said Richard Powers, Vice President, Manufacturing Industries Solutions at Compaq. "Compaq has displayed a commitment to the life sciences industry with support of organizations such as the Sanger Centre and Celera Genomics Corporation. Our partnership with AxCell shows our commitment to the future of life sciences with support for proteomics." Mr. Powers added. Using high-throughput methods, AxCell is creating a database designed to identify protein interactions and novel drug targets, which are also potentially useful in determining which compounds are likely to have the fewest side effects. Aberrations in protein pathways are at the heart of the molecular basis of many diseases. AxCell uses proprietary technology which identifies protein pathways to create the Inter-Functional Proteomic (IFP) Database. The IFP is currently under development with software partner, InforMax Inc., a Maryland based private company (www.informaxinc.com). This AxCell product is designed to enable linkage of the protein pathway data with an intuitive user interface in an enterprise system, InforMax's Software Solution for Bio-Medicine. The IFP should allow subscribers to utilize this valuable information with other existing information and algorithms. "We are //// Chucka